Disease: Major depression

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Read More »

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity

mycolabadmin

Scientists discovered that distantly related hallucinogenic mushrooms produce psilocybin, the psychoactive compound in magic mushrooms, through a shared set of genes that were likely transferred between species living in similar environments like dung and decaying wood. By sequencing the genomes of three different hallucinogenic mushroom species, researchers found nearly identical gene clusters responsible for making psilocybin, and evidence showing these genes jumped between unrelated fungal lineages. This discovery suggests that fungi in dung and wood environments may be rich sources of other bioactive compounds with potential medical applications.

Read More »

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice

mycolabadmin

This paper discusses why testing psychedelic therapies in clinical trials is more complicated than testing regular drugs. When people take psychedelics like MDMA or psilocybin, they clearly notice the effects, which makes it hard to keep the study ‘blinded’ (where neither patients nor researchers know who got the real drug). The author argues that for therapies combining drugs with counseling, this actually makes sense because the therapy itself is part of how the treatment works, not just a confounding factor. However, for stand-alone drug use, this unblinding is a real problem that makes it unclear whether the drug or people’s expectations caused the improvement.

Read More »

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Read More »

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics

mycolabadmin

Researchers created a new questionnaire called the Afterglow Inventory to measure the positive effects people experience in the days and weeks after using psychedelics like psilocybin and LSD. These ‘afterglow’ effects include improved mood, feelings of spiritual connection, increased creativity, and better relationships. The study with over 1,300 participants showed the questionnaire works well at measuring these effects, which could help researchers better understand how psychedelics might help treat depression and other conditions.

Read More »

Classic psychedelics do not affect T cell and monocyte immune responses

mycolabadmin

Researchers tested whether common psychedelic drugs (LSD, psilocin, DMT, and mescaline) directly affect human immune cells in laboratory conditions. They found that these psychedelics did not suppress T cell function or immune signaling at the doses tested. This is good news for patients with serious illnesses who might benefit from psychedelic-assisted therapy, as it suggests these treatments won’t dangerously weaken their already compromised immune systems.

Read More »

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

mycolabadmin

A 70-year-old man suffering from severe depression and anxiety caused by chronic Lyme disease and related tick-borne infections found relief after taking small doses of psilocybin mushrooms three times a week. Within days of starting treatment, his mood improved dramatically, and he remained symptom-free for two years. This case suggests that psilocybin’s ability to reduce inflammation in the brain may help patients with infectious-caused psychiatric conditions who cannot tolerate standard medications.

Read More »
Scroll to Top